Biomechanical and inflammatory pathways of IL-1β in ARDS: Insights from extensive burn injuries
Abstract
Acute Respiratory Distress Syndrome (ARDS) is a severe complication often seen in patients with extensive burns, driven by systemic inflammation mediated by interleukin-1β (IL-1β). Understanding the biomechanical and inflammatory pathways, as well as long-term complications, is critical for improving therapeutic interventions. However, existing approaches often fail to comprehensively address the interplay between IL-1β and the systemic inflammatory response, particularly in the context of biomechanical stress on lung tissue, leading to limited efficacy in mitigating ARDS-related morbidity and mortality. Furthermore, these methods lack precise strategies to predict and monitor disease progression in burn patients, especially in terms of biomechanical alterations in pulmonary function. The proposed framework emphasizes ARDS as the focal point for addressing systemic inflammation in burn patients by targeting IL-1β-mediated inflammatory pathways (IL-1β-MIP) and their biomechanical consequences. The method integrates advanced biomarker analysis and molecular-level therapeutic interventions focusing on IL-1β inhibition to assess the impact of inflammation on lung compliance and tissue stiffness. The proposed approach utilizes a combination of precision medicine, including cytokine-modulating therapies, alongside early diagnostic tools such as IL-1β serum level monitoring. This framework aims to alleviate acute symptoms and mitigate the risk of long-term complications such as pulmonary fibrosis and immune dysregulation, which are often associated with altered tissue mechanics. The findings demonstrate that targeted IL-1β modulation significantly reduces ARDS severity, improving survival rates and reducing long-term complications. IL-1β-MIP highlights the potential of personalized anti-inflammatory therapies in transforming ARDS management in patients with extensive burns, providing a foundation for future clinical advancements that integrate biomechanical insights into therapeutic strategies.
References
1. McVey MJ, Steinberg BE, Goldenberg NM. Inflammasome activation in acute lung injury. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021; 320(2): L165–L178. doi: 10.1152/ajplung.00303.2020
2. Li N, Geng C, Hou S, et al. Damage-associated molecular patterns and their signaling pathways in primary blast lung injury: New research progress and future directions. International Journal of Molecular Sciences. 2020; 21(17): 6303. doi: 10.3390/ijms21176303
3. Niri P, Saha A, Polopalli S, et al. Role of biomarkers and molecular signaling pathways in acute lung injury. Fundamental & Clinical Pharmacology. 2024; 38(4): 640–657. doi: 10.1111/fcp.12987
4. Bossardi Ramos R, Adam AP. Molecular mechanisms of vascular damage during lung injury. In: Lung Inflammation in Health and Disease. Springer International Publishing; 2021. pp. 95–107.
5. Al-Benna S. Inflammatory and coagulative pathophysiology for the management of burn patients with COVID-19: Systematic review of the evidence. Annals of Burns and Fire Disasters. 2021; 34(1): 3–9.
6. Vaughn AE, Lehmann T, Sul C, et al. CNP-miR146a Decreases Inflammation in Murine Acute Infectious Lung Injury. Pharmaceutics. 2023; 15(9): 2210. doi: 10.3390/pharmaceutics15092210
7. Xu H, Sheng S, Luo W, et al. Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup. Frontiers in Immunology. 2023; 14. doi: 10.3389/fimmu.2023.1277161
8. Ziaka M, Exadaktylos A. Exploring the lung-gut direction of the gut-lung axis in patients with ARDS. Critical Care. 2024; 28(1): 179. doi: 10.1186/s13054-024-04966-4
9. An Y, Zhang H, Wang R, et al. Biomarkers, signaling pathways, and programmed cell death in acute lung injury and its treatment with Traditional Chinese Medicine: A narrative review. European Review for Medical & Pharmacological Sciences. 2023; 27(21).
10. Yin Y, Zeng Z, Wei S, et al. Using the sympathetic system, beta blockers and alpha-2 agonists, to address acute respiratory distress syndrome. International Immunopharmacology. 2024; 139: 112670. doi: 10.1016/j.intimp.2024.112670
11. Youssef NS, Elzaitony AS, Abdel Baky NA. Diacerein attenuate LPS-induced acute lung injury via inhibiting ER stress and apoptosis: Impact on the crosstalk between SphK1/S1P, TLR4/NFκB/STAT3, and NLRP3/IL-1β signaling pathways. Life Sciences. 2022; 308: 120915. doi: 10.1016/j.lfs.2022.120915
12. O’Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine. 2021; 47(8): 899–902. doi: 10.1007/s00134-021-06419-w
13. Hu Q, Zhang S, Yang Y, et al. Extracellular vesicles in the pathogenesis and treatment of acute lung injury. Military Medical Research. 2022; 9(1). doi: 10.1186/s40779-022-00417-9
14. Guo X, Niu Z, Zhuang Y, et al. Bone marrow mesenchymal stromal cells attenuate smoke inhalation injury by regulating the M1/M2-Th17/Treg immune homeostasis axis. International Immunopharmacology. 2024; 141: 112986. doi: 10.1016/j.intimp.2024.112986
15. González-Rodríguez P, Herrero R, Sanchez G, Angel Lorente J. New insights in ARDS pathogenesis. Signa Vitae. 2022; 18(5).
16. Tan YY, Zhang DW, Yang C, et al. ASIC1a regulates airway epithelial cell pyroptosis in acute lung injury by NLRP3-Caspase1-GSDMD pathway. International Immunopharmacology. 2024; 143: 113623. doi: 10.1016/j.intimp.2024.113623
17. Lupu L, Palmer A, Huber-Lang M. Inflammation, thrombosis, and destruction: The three-headed cerberus of trauma- and SARS-CoV-2-induced ARDS. Frontiers in Immunology. 2020; 11. doi: 10.3389/fimmu.2020.584514
18. Zuo W, Tian F, Ke J, et al. Mechanisms and Research Progress of Traditional Chinese Medicine Regulating NF-κB in the Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome. Chinese Medicine and Natural Products. 2024; 04(03): e93–e105. doi: 10.1055/s-0044-1790228
19. Zheng J, Li Y, Kong X, Guo J. Exploring immune-related pathogenesis in lung injury: Providing new insights Into ALI/ARDS. Biomedicine & Pharmacotherapy. 2024; 175: 116773. doi: 10.1016/j.biopha.2024.116773
20. Huang Q, Le Y, Li S, Bian Y. Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS). Respiratory Research. 2024; 25(1): 30. doi: 10.1186/s12931-024-02678-5
21. Young MD, Cancio TS, Thorpe CR, et al. Circulatory HMGB1 is an early predictive and prognostic biomarker of ARDS and mortality in a swine model of polytrauma. Frontiers in Immunology. 2023; 14. doi: 10.3389/fimmu.2023.1227751
22. Xiang Y, Pan B han, Zhang J, et al. Suppression of overactivated immunity in the early stage is the key to improve the prognosis in severe burns. Frontiers in Immunology. 2024; 15. doi: 10.3389/fimmu.2024.1455899
23. Bezerra FS, Lanzetti M, Nesi RT, et al. Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries. Antioxidants. 2023; 12(3): 548. doi: 10.3390/antiox12030548
24. Zhu W, Zhang Y, Wang Y. Immunotherapy strategies and prospects for acute lung injury: Focus on immune cells and cytokines. Frontiers in Pharmacology. 2022; 13. doi: 10.3389/fphar.2022.1103309
25. Korkmaz HI, Flokstra G, Waasdorp M, et al. The Complexity of the Post-Burn Immune Response: An Overview of the Associated Local and Systemic Complications. Cells. 2023; 12(3): 345. doi: 10.3390/cells12030345
26. Available online: https://datasetsearch.research.google.com/search?src=0&query=Inflammatory%20Pathways%20of%20IL-1%CE%B2%20in%20ARDS&docid=L2cvMTF5OThwdzlxNg%3D%3D (accessed on 3 December 2024).
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
